BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group (Q36145443)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group (English)

1 reference

Europe PubMed Central

12 August 2017

1 reference

based on heuristic

inferred from title

Alexander Dobrovic

7

1 reference

Europe PubMed Central

12 August 2017

12

1 reference

Europe PubMed Central

12 August 2017

object named as

Kathryn Alsop

1

0 references

object named as

Anna deFazio

4

0 references

object named as

David Bowtell

13

0 references

Penelope M. Webb

object named as

Penelope M Webb

9

0 references

author name string

Sian Fereday

2

1 reference

Europe PubMed Central

12 August 2017

Cliff Meldrum

3

1 reference

Europe PubMed Central

12 August 2017

Catherine Emmanuel

5

1 reference

Europe PubMed Central

12 August 2017

Joshy George

6

1 reference

Europe PubMed Central

12 August 2017

Michael J Birrer

8

1 reference

Europe PubMed Central

12 August 2017

Colin Stewart

10

1 reference

Europe PubMed Central

12 August 2017

Michael Friedlander

11

1 reference

Europe PubMed Central

12 August 2017

Gillian Mitchell

14

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

18 June 2012

1 reference

Europe PubMed Central

12 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

12 August 2017

30

1 reference

Europe PubMed Central

12 August 2017

2654-2663

1 reference

Europe PubMed Central

12 August 2017

21

1 reference

Europe PubMed Central

12 August 2017

Rethinking ovarian cancer: recommendations for improving outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Integrated genomic analyses of ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Resistance to therapy caused by intragenic deletion in BRCA2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Improved survival in BRCA2 carriers with ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Cancer of the ovary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

2 October 2017

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

Improved survival in women with BRCA-associated ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

23 September 2018

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

5 December 2018

Prognostic impact ofBRCA1 pathogenic andBRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3413277

5 December 2018

Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can we now agree to use the same definition to measure response according to CA-125?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22711857

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.39.8545

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36145443&oldid=1992033861"